Creating a new treatment for skin fibrosis in scleroderma patients
Development of a Novel Therapeutic Agent for Skin Fibrosis
This study is testing a new treatment called M10 to help improve skin problems caused by scleroderma, a condition that makes the skin stiff and thick, and it's designed to be safe and effective for patients dealing with this issue.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fibrobiologics, LLC NIH-funded |
| Lab location | 1 site (Charleston, United States) |
| Project ID | NIH-11006900 on NIH RePORTER |
What this research studies
This research focuses on developing a novel peptide therapeutic agent, M10, aimed at treating skin fibrosis associated with scleroderma, an autoimmune disease. The study will investigate the antifibrotic activity of M10 using primary skin fibroblasts from affected patients. By leveraging advances in peptide formulation and synthesis, the research aims to create a drug that is highly specific and has low toxicity, potentially improving the quality of life for patients suffering from this debilitating condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with scleroderma who experience significant skin fibrosis.
Not a fit: Patients with scleroderma who do not have skin fibrosis or those with other unrelated conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new effective treatment for skin fibrosis in scleroderma patients, improving their skin condition and overall health.
How similar studies have performed: While there have been advancements in treatments for scleroderma, the specific approach of using the peptide M10 is novel and has not been extensively tested in this context.
Where this research is happening
Charleston, United States
- Fibrobiologics, LLC — Charleston, United States (Active)
Researchers
- Principal investigator: Bogatkevich, Galina S — Fibrobiologics, LLC
- Study coordinator: Bogatkevich, Galina S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.